Amersham Biosciences

News Amersham Biosciences

• BioCision appoints chief operating officer and expands corporate advisory board

  BioCision LLC announced the expansion of its management team, with the appointment of industry veteran Hugh Douglas to the position of chief operating officer. The company also announced that it has added a group of leading industry experts to BioCision’s corporate advisory board. These appointments more

• Fluorotechnics appoints European biotech veteran Lars Utterman as non-executive director

  Fluorotechnics Limited has appointed Lars Utterman as a non-executive director. Mr Utterman has over 30 years sales and general management experience with biotechnology companies. Currently, he is CEO of German-based IonGate Biosciences, a company specialising in developing systems for transporter more

• Fluorotechnics appoints Mark Weller to head up their UK Sales and Marketing operation

  Fluorotechnics announced the appointment of Mark Weller as head of their UK Sales team. According to the copmpany, Mark brings to Fluorotechnics a wealth of sales and technical experience, having served as a leading sales specialist and key-account manager for protein analysis at GE Healthcare (prev more

White papers Amersham Biosciences

• Quantitative Chromatin Immunoprecipitation Using the LightCycler® 480 System
  

  Antigen processing and presentation play a critical role in immune surveillance. Peptides derived from self, viral, or tumor-associated antigens are generated in the cytoplasm by the proteasome. Transporter associated with antigen processing (TAP), a member of the ATP-binding cassette (ABC) transporter family, functions by transporting these peptides from the cytoplasm to the lumen of the endoplasmic reticulum (ER), where each peptide forms a ternary complex with beta-2 microglobulin (ß2m) and major histocompatibility complex (MHC) class I heavy chain. These complexes are then transported to the cell surface and recognized by cytotoxic T lymphocytes (CTLs), which eventually kill cells that present non-self antigens. more

• Simulated Moving Bed Chromatography: from chiral molecules to biocompounds
  

  The Simulated moving bed (SMB) technology was developed in the '60s and used for large-scale separations of hydrocarbons in the oil industry. The SMB concept has been extended towards new fields of application since then, first in the large-scale food industry, e.g. separation of sugars, and lately in the separation of fine chemicals, particularly chiral molecules where it is now an established technique more

Websites Amersham Biosciences